BalÃ¡zs SÃœmegi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10780334/publications.pdf

Version: 2024-02-01

86	5,052	94269 37	88477 70
papers	citations	h-index	g-index

86	86	86	6453
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	BGP-15 Protects against Heart Failure by Enhanced Mitochondrial Biogenesis and Decreased Fibrotic Remodelling in Spontaneously Hypertensive Rats. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	12
2	Cyclophilin Dâ€dependent mitochondrial permeability transition amplifies inflammatory reprogramming in endotoxemia. FEBS Open Bio, 2021, 11, 684-704.	1.0	10
3	Amiodaroneâ€™s major metabolite, desethylamiodarone inhibits proliferation of B16-F10 melanoma cells and limits lung metastasis formation in an in vivo experimental model. PLoS ONE, 2020, 15, e0239088.	1.1	4
4	Role of Akt Activation in PARP Inhibitor Resistance in Cancer. Cancers, 2020, 12, 532.	1.7	49
5	Mitochondrial Protection by PARP Inhibition. International Journal of Molecular Sciences, 2020, 21, 2767.	1.8	21
6	PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells. Frontiers in Physiology, 2019, 10, 538.	1.3	16
7	PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1Î±, Nrf2, and NFÎºB. , 2019, 60, 1478.		31
8	PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome. Biochemical Pharmacology, 2019, 162, 98-108.	2.0	33
9	Activation of mitochondrial fusion provides a new treatment for mitochondria-related diseases. Biochemical Pharmacology, 2018, 150, 86-96.	2.0	63
10	Opportunities for the repurposing of PARP inhibitors for the therapy of nonâ€oncological diseases. British Journal of Pharmacology, 2018, 175, 192-222.	2.7	160
11	Amiodaroneâ€™s major metabolite, desethylamiodarone, induces apoptosis in human cervical cancer cells. Canadian Journal of Physiology and Pharmacology, 2018, 96, 1004-1011.	0.7	4
12	PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway. Free Radical Biology and Medicine, 2017, 108, 770-784.	1.3	76
13	Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	86
14	Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats. PLoS ONE, 2017, 12, e0174401.	1.1	12
15	Desethylamiodaroneâ€"A metabolite of amiodaroneâ€"Induces apoptosis on T24 human bladder cancer cells via multiple pathways. PLoS ONE, 2017, 12, e0189470.	1.1	17
16	Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors. Oncotarget, 2017, 8, 50221-50239.	0.8	20
17	PARP inhibition and postinfarction myocardial remodeling. International Journal of Cardiology, 2016, 217, S52-S59.	0.8	14
18	Role of Mitochondrial Network Stabilisation by a Human Small Heat Shock Protein in Tumour Malignancy. Journal of Cancer, 2015, 6, 470-476.	1.2	6

#	Article	IF	Citations
19	Lack of cyclophilin D protects against the development of acute lung injury in endotoxemia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2563-2573.	1.8	12
20	Anti-inflammatory effects of a triple-bond resveratrol analog: Structure and function relationship. European Journal of Pharmacology, 2015, 748, 61-67.	1.7	25
21	Cyclophilin D disruption attenuates lipopolysaccharide-induced inflammatory response in primary mouse macrophages. Biochemistry and Cell Biology, 2015, 93, 241-250.	0.9	19
22	Novel Mechanisms of Sildenafil in Pulmonary Hypertension Involving Cytokines/Chemokines, MAP Kinases and Akt. PLoS ONE, 2014, 9, e104890.	1.1	37
23	PARP inhibitor attenuated colony formation can be restored by MAP kinase inhibitors in different irradiated cancer cell lines. International Journal of Radiation Biology, 2014, 90, 1152-1161.	1.0	2
24	Quantification of Conversion Degree and Monomer Elution from Dental Composite Using HPLC and Micro-Raman Spectroscopy. Chromatographia, 2014, 77, 1137-1144.	0.7	38
25	Estradiol and isotype-selective estrogen receptor agonists modulate the mesocortical dopaminergic system in gonadectomized female rats. Brain Research, 2014, 1583, 1-11.	1.1	35
26	Resveratrol and Oxidative Stress in Diabetes Mellitus. , 2014, , 99-109.		7
27	A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 935-944.	1.8	23
28	PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3Î² and Several PKC Isoforms. PLoS ONE, 2014, 9, e102148.	1.1	29
29	Quercetin Increases the Efficacy of Glioblastoma Treatment Compared to Standard Chemoradiotherapy by the Suppression of PI-3-Kinase-Akt Pathway. Nutrition and Cancer, 2013, 65, 1059-1066.	0.9	37
30	TRAF6 is functional in inhibition of TLR4-mediated NF-ÎºB activation by resveratrol. Journal of Nutritional Biochemistry, 2013, 24, 819-823.	1.9	74
31	Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness. Current Pharmaceutical Design, 2013, 19, 309-346.	0.9	61
32	Antioxidant and Anti-Inflammatory Effects in RAW264.7 Macrophages of Malvidin, a Major Red Wine Polyphenol. PLoS ONE, 2013, 8, e65355.	1.1	128
33	PARP Inhibition Attenuates Acute Kidney Allograft Rejection by Suppressing Cell Death Pathways and Activating PI-3K-Akt Cascade. PLoS ONE, 2013, 8, e81928.	1.1	14
34	Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation. Molecular Cancer, 2012, 11, 34.	7.9	16
35	BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Molecular and Cellular Biochemistry, 2012, 365, 129-137.	1.4	52
36	Evidence on Cholesterol-Controlled Lipid Raft Interaction of the Small Heat Shock Protein HSPB11. Heat Shock Proteins, 2012, , 75-85.	0.2	6

#	Article	IF	Citations
37	Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition, 2011, 106, 383-389.	1.2	553
38	Induction of mitochondrial destabilization and necrotic cell death by apolar mitochondria-directed SOD mimetics. Mitochondrion, 2011, 11, 476-487.	1.6	9
39	BGP-15 inhibits caspase-independent programmed cell death in acetaminophen-induced liver injury. Toxicology and Applied Pharmacology, 2010, 243, 96-103.	1.3	61
40	TIP47 confers resistance to taxol-induced cell death by preventing the nuclear translocation of AIF and Endonuclease G. European Journal of Cell Biology, 2010, 89, 853-861.	1.6	10
41	Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: A new mechanism for the cytoplasmic effect of PARP-1 activation. Free Radical Biology and Medicine, 2010, 49, 1978-1988.	1.3	53
42	Facilitation of Mitochondrial Outer and Inner Membrane Permeabilization and Cell Death in Oxidative Stress by a Novel Bcl-2 Homology 3 Domain Protein. Journal of Biological Chemistry, 2010, 285, 2140-2151.	1.6	36
43	Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death. Brain, 2010, 133, 822-834.	3.7	93
44	Suppressing LPS-induced early signal transduction in macrophages by a polyphenol degradation product: a critical role of MKP-1. Journal of Leukocyte Biology, 2010, 89, 105-111.	1.5	40
45	PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovascular Research, 2009, 83, 501-510.	1.8	61
46	Ferulaldehyde, a Water-Soluble Degradation Product of Polyphenols, Inhibits the Lipopolysaccharide-Induced Inflammatory Response in Mice. Journal of Nutrition, 2009, 139, 291-297.	1.3	34
47	PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochemical Pharmacology, 2009, 77, 1348-1357.	2.0	47
48	Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAP kinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in U-937 human macrophage cells. European Journal of Cell Biology, 2009, 88, 753-763.	1.6	25
49	Alcohol-free red wine inhibits isoproterenol-induced cardiac remodeling in rats by the regulation of Akt1 and protein kinase C Î±/Î² II. Journal of Nutritional Biochemistry, 2009, 20, 418-425.	1.9	33
50	Prevalent role of Akt and ERK activation in cardioprotective effect of Ca2+ channel- and beta-adrenergic receptor blockers. Molecular and Cellular Biochemistry, 2009, 321, 155-164.	1.4	24
51	Protection Against Chronic Hypoperfusion-Induced Retinal Neurodegeneration by PARP Inhibition via Activation of PI-3-kinase Akt Pathway and Suppression of JNK and p38 MAP Kinases. Neurotoxicity Research, 2009, 16, 68-76.	1.3	48
52	New Poly(ADP-ribose) Polymerase-1 Inhibitors with Antioxidant Activity Based on 4-Carboxamidobenzimidazole-2-ylpyrroline and -tetrahydropyridine Nitroxides and Their Precursors. Journal of Medicinal Chemistry, 2009, 52, 1619-1629.	2.9	37
53	Effect of L-2286, a Poly(ADP-ribose)polymerase Inhibitor and Enalapril on Myocardial Remodeling and Heart Failure. Journal of Cardiovascular Pharmacology, 2008, 52, 253-261.	0.8	23
54	Correlation between the progressive cytoplasmic expression of a novel small heat shock protein (Hsp16.2) and malignancy in brain tumors. BMC Cancer, 2007, 7, 233.	1.1	36

#	Article	IF	Citations
55	Preventing apoptotic cell death by a novel small heat shock protein. European Journal of Cell Biology, 2007, 86, 161-171.	1.6	67
56	Inhibition of cell death by a novel 16.2 kD heat shock protein predominantly via Hsp90 mediated lipid rafts stabilization and Akt activation pathway. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 97-112.	2.2	49
57	Induction of necrotic cell death and mitochondrial permeabilization by heme binding protein 2/SOUL. FEBS Letters, 2006, 580, 6447-6454.	1.3	37
58	PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3Î² pathwayâ˜†. Journal of Molecular and Cellular Cardiology, 2006, 41, 149-159.	0.9	52
59	A novel SOD-mimetic permeability transition inhibitor agent protects ischemic heart by inhibiting both apoptotic and necrotic cell death. Free Radical Biology and Medicine, 2006, 41, 835-848.	1.3	36
60	Critical role of PI3-kinase/Akt activation in the PARP inhibitor induced heart function recovery during ischemiaâ€“reperfusion. Biochemical Pharmacology, 2006, 71, 441-452.	2.0	50
61	Synthesis and evaluation of the permeability transition inhibitory characteristics of paramagnetic and diamagnetic amiodarone derivatives. Bioorganic and Medicinal Chemistry, 2005, 13, 2629-2636.	1.4	22
62	Pivotal Role of Akt Activation in Mitochondrial Protection and Cell Survival by Poly(ADP-ribose)polymerase-1 Inhibition in Oxidative Stress. Journal of Biological Chemistry, 2005, 280, 35767-35775.	1.6	151
63	The Role of Akt and Mitogen-Activated Protein Kinase Systems in the Protective Effect of Poly(ADP-Ribose) Polymerase Inhibition in Langendorff Perfused and in Isoproterenol-Damaged Rat Hearts. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 273-282.	1.3	44
64	Regulation of Kinase Cascades and Transcription Factors by a Poly(ADP-Ribose) Polymerase-1 Inhibitor, 4-Hydroxyquinazoline, in Lipopolysaccharide-Induced Inflammation in Mice. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 247-255.	1.3	119
65	Functional analyses of placental proteinâ€ƒ13/galectin-13. FEBS Journal, 2004, 271, 1065-1078.	0.2	142
66	Inhibition of ADP-Evoked Platelet Aggregation by Selected Poly(ADP-Ribose) Polymerase Inhibitors. Journal of Cardiovascular Pharmacology, 2004, 43, 423-431.	0.8	9
67	Myocardial protection by selective poly(ADP-ribose) polymerase inhibitors. Experimental and Clinical Cardiology, 2004, 9, 17-20.	1.3	7
68	Akt activation induced by an antioxidant compound during ischemia-reperfusion. Free Radical Biology and Medicine, 2003, 35, 1051-1063.	1.3	41
69	Impact of a novel cardioprotective agent on the ischaemia-reperfusion-induced Akt kinase activation. Biochemical Pharmacology, 2003, 66, 2263-2272.	2.0	18
70	Concentration dependent mitochondrial effect of amiodarone. Biochemical Pharmacology, 2003, 65, 1115-1128.	2.0	44
71	Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochemical Pharmacology, 2003, 65, 1373-1382.	2.0	620
72	Protective Effect of Amiodarone but Not N- Desethylamiodarone on Postischemic Hearts through the Inhibition of Mitochondrial Permeability Transition. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 615-625.	1.3	38

#	Article	IF	Citations
73	2,2,5,5-Tetramethylpyrroline-Based Compounds in Prevention of Oxyradical-induced Myocardial Damage. Journal of Cardiovascular Pharmacology, 2002, 40, 854-867.	0.8	15
74	Novel phenanthridinone inhibitors of poly(adenosine 5â€²-diphosphate-ribose) synthetase: Potent cytoprotective and antishock agents*. Critical Care Medicine, 2002, 30, 1071-1082.	0.4	187
75	Reduction of acute photodamage in skin by topical application of a novel PARP inhibitor. Biochemical Pharmacology, 2002, 63, 921-932.	2.0	43
76	BGP-15â€”a novel poly(ADP-ribose) polymerase inhibitorâ€”protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochemical Pharmacology, 2002, 63, 1099-1111.	2.0	92
77	Placental protein 17b overexpression in human uterine cervical cancer. Journal of Obstetrics and Gynaecology Research, 2002, 28, 8-12.	0.6	1
78	Effect of Poly(ADP-Ribose) Polymerase Inhibitors on the Ischemia-Reperfusion-Induced Oxidative Cell Damage and Mitochondrial Metabolism in Langendorff Heart Perfusion System. Molecular Pharmacology, 2001, 59, 1497-1505.	1.0	136
79	Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radical Biology and Medicine, 2001, 31, 548-558.	1.3	220
80	BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochemical Pharmacology, 2000, 59, 937-945.	2.0	76
81	Molecular mechanism of the short-term cardiotoxicity caused by 2â€²,3â€²-dideoxycytidine (ddC): modulation of reactive oxygen species levels and ADP-ribosylation reactions. Biochemical Pharmacology, 1999, 58, 1915-1925.	2.0	47
82	Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radical Biology and Medicine, 1999, 26, 309-317.	1.3	122
83	Enhanced ADP-ribosylation and its diminution by lipoamide after ischemia-reperfusion in perfused rat heart. Free Radical Biology and Medicine, 1999, 27, 1103-1113.	1.3	41
84	Kinetic advantage of the interaction between the fatty acid Î²-oxidation enzymes and the complexes of the respiratory chain. Lipids and Lipid Metabolism, 1991, 1081, 121-128.	2.6	37
85	Cytochrome oxidase deficiency affecting the structure of the myofibre and the shape of mitochondrial cristae membrane. Clinica Chimica Acta, 1990, 192, 9-18.	0.5	11
86	Studies on a possible molecular basis for the structure of mitochondrial cristae. Journal of Molecular Recognition, 1988, 1, 19-24.	1.1	6